D Weycker

Summary

Affiliation: Policy Analysis Inc
Country: USA

Publications

  1. ncbi Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice
    D Weycker
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, USA
    Osteoporos Int 24:1483-9. 2013
  2. ncbi Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
    Derek Weycker
    Policy Analysis Inc, Brookline, MA, USA
    BMC Health Serv Res 13:60. 2013
  3. ncbi Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice
    Derek Weycker
    Policy Analysis Inc, PAI, 4 Davis Court, Brookline, MA, 02445, USA
    BMC Cancer 12:362. 2012
  4. ncbi Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years
    Derek Weycker
    Policy Analysis Inc, Brookline, MA 02445, USA
    Vaccine 30:5437-44. 2012
  5. ncbi Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy
    Derek Weycker
    Policy Analysis Inc, Four Davis Court, Brookline, MA 02445, USA
    Am J Clin Oncol 35:267-74. 2012
  6. ncbi Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice
    Derek Weycker
    Policy Analysis Inc, Four Davis Court, Brookline, MA 02445, USA
    Breast Cancer Res Treat 133:301-10. 2012
  7. ncbi Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer
    Derek Weycker
    Policy Analysis Inc, Brookline, MA 02445, USA
    Chemotherapy 58:8-18. 2012
  8. ncbi Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
    Montserrat Vera-Llonch
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, USA
    BMC Health Serv Res 11:305. 2011
  9. ncbi Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
    Montserrat Vera-Llonch
    Policy Analysis Inc PAI, Brookline, MA, USA
    BMC Cancer 11:250. 2011
  10. ncbi Compliance with drug therapy for postmenopausal osteoporosis
    D Weycker
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA, 02445, USA
    Osteoporos Int 17:1645-52. 2006

Detail Information

Publications32

  1. ncbi Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice
    D Weycker
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, USA
    Osteoporos Int 24:1483-9. 2013
    ..Our study suggests that better adherence with bisphosphonates confers tangible benefits in terms of graded increases in bone mineral density. Interventions to improve drug adherence should be an important component of disease management...
  2. ncbi Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
    Derek Weycker
    Policy Analysis Inc, Brookline, MA, USA
    BMC Health Serv Res 13:60. 2013
    ..The accuracy of methods previously used to identify FN in such databases has not been formally evaluated...
  3. ncbi Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice
    Derek Weycker
    Policy Analysis Inc, PAI, 4 Davis Court, Brookline, MA, 02445, USA
    BMC Cancer 12:362. 2012
    ..Economic implications of chemotherapy-induced febrile neutropenia (FN) in European and Australian clinical practice are largely unknown...
  4. ncbi Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years
    Derek Weycker
    Policy Analysis Inc, Brookline, MA 02445, USA
    Vaccine 30:5437-44. 2012
    ..The potential public health and economic impact of PCV13 in this population is unknown...
  5. ncbi Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy
    Derek Weycker
    Policy Analysis Inc, Four Davis Court, Brookline, MA 02445, USA
    Am J Clin Oncol 35:267-74. 2012
    ....
  6. ncbi Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice
    Derek Weycker
    Policy Analysis Inc, Four Davis Court, Brookline, MA 02445, USA
    Breast Cancer Res Treat 133:301-10. 2012
    ..In the current era of US clinical practice, chemotherapy dose delays and dose reductions are common among women with ESBC receiving frequently used myelosuppressive dose-dense, as well as conventional, chemotherapy regimens...
  7. ncbi Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer
    Derek Weycker
    Policy Analysis Inc, Brookline, MA 02445, USA
    Chemotherapy 58:8-18. 2012
    ....
  8. ncbi Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
    Montserrat Vera-Llonch
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, USA
    BMC Health Serv Res 11:305. 2011
    ..To characterize healthcare resource utilization and costs in patients with metastatic lung cancer receiving chemotherapy in the US...
  9. ncbi Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
    Montserrat Vera-Llonch
    Policy Analysis Inc PAI, Brookline, MA, USA
    BMC Cancer 11:250. 2011
    ..In this study, we characterize healthcare utilization and costs in the US among women with metastatic breast cancer receiving chemotherapy as their principal treatment modality...
  10. ncbi Compliance with drug therapy for postmenopausal osteoporosis
    D Weycker
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA, 02445, USA
    Osteoporos Int 17:1645-52. 2006
    ..Patient compliance with pharmacotherapy for osteoporosis is typically poor in clinical practice; less frequent dosing with bisphosphonates may improve compliance...
  11. ncbi Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan
    Derek Weycker
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    Blood Press 17:5-12. 2008
    ..To describe the real-world effectiveness of amlodipine add-on therapy for hypertensive patients receiving valsartan...
  12. ncbi Clinical and economic burden of pneumococcal disease in older US adults
    Derek Weycker
    Policy Analysis Inc PAI, Brookline, MA 02445, United States
    Vaccine 28:4955-60. 2010
    ..7 billion and $1.8 billion, respectively. Pneumococcal disease remains a substantial burden among older US adults, despite increased coverage with PPV23 and indirect benefits afforded by PCV7 vaccination of young children...
  13. ncbi Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq
    Derek Weycker
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, United States
    Vaccine 27:4930-7. 2009
    ..On an overall basis, Rotarix would reduce costs by $77.2 million (95% CI $71.5-$86.5). Similar reductions with Rotarix were estimated to occur under an assumption of incomplete immunization of children...
  14. ncbi Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study
    Derek Weycker
    Policy Analysis Inc, Brookline, Massachusetts 02445, USA
    Clin Ther 31:1069-81. 2009
    ..However, there is limited information on the comparative effectiveness of these agents in clinical practice...
  15. ncbi Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis
    Derek Weycker
    Policy Analysis Inc, Brookline, Massachusetts 02445, USA
    Clin Ther 27:646-56. 2005
    ..The aim of this work was to retrospectively examine the costs of therapy with etanercept and infliximab, among patients aged > or = 65 years with rheumatoid arthritis (RA), from a health-care system perspective...
  16. ncbi Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan
    Derek Weycker
    Policy Analysis Inc, Four Davis Court, Brookline, MA 02445, USA
    Blood Press Suppl 2:5-12. 2008
    ..To describe the real-world effectiveness of amlodipine add-on therapy for hypertensive patients receiving valsartan...
  17. ncbi Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan
    Derek Weycker
    Policy Analysis Inc, Brookline, MA 02445, USA
    Blood Press Suppl 17:5-12. 2008
    ..CONCLUSIONS: Adding amlodipine to valsartan for treatment of hypertension results in clinically meaningful reductions in blood pressure, on an overall basis and in high-risk subgroups who may benefit the most from blood pressure control...
  18. ncbi Compliance with osteoporosis drug therapy and risk of fracture
    D Weycker
    Policy Analysis Inc PAI, Four Davis Court, Brookline, MA 02445, USA
    Osteoporos Int 18:271-7. 2007
    ..Patient compliance with osteoporosis drug therapy is often poor in clinical practice and may be associated with higher risk of fracture...
  19. ncbi Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine
    D Weycker
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    J Hum Hypertens 21:374-80. 2007
    ..79, 95% CI 0.68-0.92). Our study thus corroborates the finding from VALUE that diabetes risk is lower for patients who receive valsartan versus amlodipine, and extends this finding to a 'real-world' setting...
  20. ncbi Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil
    Derek Weycker
    Policy Analysis Inc, Brookline, Massachusetts 02445, USA
    Curr Med Res Opin 23:1187-97. 2007
    ..The efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease (AD) receiving stable doses of donepezil were recently demonstrated in a phase III trial. The cost-effectiveness of such therapy is unknown...
  21. ncbi Risk-factor clustering and cardiovascular disease risk in hypertensive patients
    Derek Weycker
    Policy Analysis, Inc, Brookline, Massachusetts 02445, USA
    Am J Hypertens 20:599-607. 2007
    ..Patients with hypertension often have other major risk factors for cardiovascular disease (CVD). Little is known, however, about the extent of risk-factor clustering in these patients and its importance in CVD risk and medical-care costs...
  22. ncbi Cost of neutropenic complications of chemotherapy
    D Weycker
    Policy Analysis Inc, Brookline, MA 02445, USA
    Ann Oncol 19:454-60. 2008
    ..Cost of neutropenic complications of myelosuppressive chemotherapy has been reported to be substantial. Prior research, however, has focused on initial hospitalization only and has failed to account for follow-on care...
  23. ncbi Blood pressure control in patients initiating antihypertensive therapy
    Derek Weycker
    Policy Analysis Inc, Brookline, MA 02445, USA
    Ann Pharmacother 42:169-76. 2008
    ..Although information concerning the attainment of goal blood pressure for patients commencing antihypertensive therapy is available from controlled trials, no studies have examined this issue in the context of typical clinical practice...
  24. ncbi Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
    Derek Weycker
    Policy Analysis Inc, Brookline, MA 02445, USA
    Ann Pharmacother 40:402-7. 2006
    ..In clinical practice, however, many patients receive shorter courses of therapy, even though the effectiveness of this regimen is unknown...
  25. ncbi Excess risk of diabetes in persons with hypertension
    Derek Weycker
    Policy Analysis Inc PAI, Brookline, MA 02445, USA
    J Diabetes Complications 23:330-6. 2009
    ..Whether, and to what extent, this risk may vary across subgroups defined on the basis of important clinical characteristics has not been well characterized...
  26. ncbi Population-wide benefits of routine vaccination of children against influenza
    Derek Weycker
    Policy Analysis Inc, Four Davis Court, Brookline, MA 02445, USA
    Vaccine 23:1284-93. 2005
    ..Similar reductions were estimated to occur in influenza-related mortality and economic costs...
  27. ncbi Long-term mortality and medical care charges in patients with severe sepsis
    Derek Weycker
    Policy Analysis Inc, Brookline, MA, USA
    Crit Care Med 31:2316-23. 2003
    ..Hospitalization accounted for the largest component of total medical care charges. CONCLUSIONS: Mortality and economic costs are high in patients with severe sepsis, during the period of acute illness as well as subsequently...
  28. ncbi Benefits and risks of live attenuated influenza vaccine in young children
    Gerry Oster
    Policy Analysis, Inc, Brookline, MA 02445, USA
    Am J Manag Care 16:e235-44. 2010
    ....
  29. ncbi Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women
    Charu Taneja
    Policy Analysis Inc, Brookline, Massachusetts 02445, USA
    J Am Coll Radiol 6:171-9. 2009
    ..The aim of this study was to estimate the cost effectiveness of breast cancer screening with contrast-enhanced magnetic resonance imaging (MRI), with and without adjunctive x-ray mammography (XM), compared with XM alone in high-risk women...
  30. ncbi 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series
    Stephen I Pelton
    Boston University Schools of Medicine and Public Health and Boston Medical Center, Boston, MA, United States
    Vaccine 28:1575-82. 2010
    ....
  31. ncbi Response to Lamotte et Al. "A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients."
    John Edelsberg
    Diabetes Care 25:1899-900. 2002
  32. ncbi The clinical course of patients with idiopathic pulmonary fibrosis
    Fernando J Martinez
    University of Michigan, Ann Arbor, Michigan 48109, USA
    Ann Intern Med 142:963-7. 2005
    ..Prospective data defining the clinical course in idiopathic pulmonary fibrosis (IPF) are sparse...